Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study — Stephanie Licata (2017) | RDL Network
Natalizumab vs fingolimod in patients with active relapsing-remitting multiple sclerosis (RRMS): comparative MRI assessments of disease activity from reveal, a randomized, head-to-head phase 4 study
Helmut Butzkueven, Stephanie Licata, Douglas Jeffery, Douglas L. Arnold, Massimo Filippi, Jeroen J.G. Geurts, Sourav Santra, Nolan Campbell, Pei‐Ran Ho
Paolo Preziosa, Maria A. Rocca, Gianna Carla Riccitelli, Mariaemma Rodegher, Massimiliano Copetti, Lucia Moiola, Francesco Mele, Andrea Falini, Giancarlo Comi, Massimo Filippi
Giacomo P. Comi, Annalisa Pulizzi, Marco Rovaris, Oded Abramsky, T. Arbizu, А. Н. Бойко, Ralf Gold, Eva Havrdová, Sámuel Komoly, Krzysztof Selmaj, Basil Sharrack, Massimo Filippi
Discussion(0)
No comments yet. Be the first to comment.